Archive: Ross Marchand
Ross Marchand is a Catalyst Policy Fellow and the director of policy for the Taxpayers Protection Alliance. He focuses on a range of issues, ranging from health-care reform to internet regulation to Postal Service-related issues. Ross is an alumnus of the Mercatus Center MA Fellowship at George Mason University, where he received his MA in economics in 2016. He has interned for the Texas Public Policy Foundation and the American Legislative Exchange Council, analyzing and blogging on a variety of public policy issues.
Let’s Ditch the Census
Innovation in enumeration can lead to more accurate data, giving policymakers a wealth of useful information without the stain of politics.
Charging Patients More Upfront Leads to More Affordable Healthcare
More skin in the game means lower costs for consumers and eventually taxpayers via lower federal health program costs.
UN Biodiversity Report Confirms the Sky Is Not Falling
The UN report (subtly) admits what many in the press won’t: indicators aren’t so bad, and capitalism can help save the environment.
Debate in America has Grown Too Fossilized
Take a Journey Outside Your Comfort Zone
The most interesting thoughts and conclusions come when the mind actually grapples with different ideas about the world.
State Flexibility Is Key to Improving Medicaid
With greater experimentation, states can turn around Medicaid’s lackluster outcomes and help millions of beneficiaries lead better lives.
The Middle-Class Is Hollowing Out, and That’s Okay
Societies can indeed become more prosperous on the whole, even as their middle classes hollow out.
Choice and Markets Are Keys to Healthy Living
It’ll take a thriving marketplace of ideas and innovation to make America and the rest of the world a healthier place.
Market-Based Medicine Beats Grim Prognosis
America may have a dysfunctional healthcare system, but at least there’s a glimmer of hope for taxpayers and consumers.
War on Cancer Progress Depends on Market Innovation
The private sector tends to do a better job of finding the “sweet spot” for research spending, leading to blockbuster new drugs and innovation.